Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SY001 (CellOrigin Biotechnology)
- Development stage
- Unknown
- Lead developer
- CellOrigin Biotechnology
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intraperitoneal
01
Overview
SY001 is an autologous chimeric antigen receptor macrophage (CAR-M) therapy targeting mesothelin-expressing solid tumors. Developed by CellOrigin Biotechnology (Hangzhou) Co., Ltd., it involves the genetic modification of patient-derived peripheral blood mononuclear cell (PBMC) macrophages to express a CAR specific for mesothelin. This approach leverages the innate ability of macrophages to infiltrate solid tumors and modulate the tumor microenvironment. It is being investigated for advanced solid tumors, including ovarian and pancreatic cancers, both as a monotherapy and in combination with immune checkpoint inhibitors like tislelizumab. SY001 is designed to promote phagocytosis of tumor cells and stimulate a broader anti-tumor immune response.
- Other names
- CAR-macrophage therapyanti-mesothelin CAR-M
02
Targets
Mesothelin
Beyond the preview
Go deeper on SY001 (CellOrigin Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SY001 (CellOrigin Biotechnology).